Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential of (a) outcome-based payment models and (b) risk sharing partnerships with industry to improve access to diabetes technology to support (i) monitoring, (ii) self-management and (iii) prevention.

When it comes to determining a fair reimbursement price for new products similar to those already listed in the Drugs Tariff, NHS Prescription Services (part of the NHS Business Service Authority) will aim to ensure that the agreed price is broadly in line with comparable products.

The Department and NHS Prescription Services have a duty to ensure that the National Health Service gets value for money. Therefore, applicants requesting a listing for new products or treatment regimens for which there are no listed comparators should provide satisfactory evidence of improved outcomes/savings/patient benefits commensurate with the requested price. Before any medical device is listed in the Tariff, NHS Prescription Services will negotiate a fair reimbursement with the applicant.